INT159

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1975
Last Reported 2010
Negated 9
Speculated 10
Reported most in Abstract
Documents 416
Total Number 427
Disease Relevance 55.34
Pain Relevance 171.80

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (Prl)
Anatomy Link Frequency
pituitary 67
lactotrophs 18
body 18
anterior pituitary 18
hypothalamus 13
Prl (Rattus norvegicus)
Pain Link Frequency Relevance Heat
antagonist 1228 100.00 Very High Very High Very High
Dopamine 1104 100.00 Very High Very High Very High
agonist 740 100.00 Very High Very High Very High
narcan 366 100.00 Very High Very High Very High
Morphine 316 100.00 Very High Very High Very High
Opioid 238 100.00 Very High Very High Very High
noradrenaline 128 100.00 Very High Very High Very High
Potency 75 100.00 Very High Very High Very High
opioid receptor 73 100.00 Very High Very High Very High
anesthesia 67 100.00 Very High Very High Very High
Disease Link Frequency Relevance Heat
Stress 1258 100.00 Very High Very High Very High
Galactorrhea 152 100.00 Very High Very High Very High
Thyroid Disease 92 100.00 Very High Very High Very High
Reprotox - General 1 69 100.00 Very High Very High Very High
Syndrome 51 100.00 Very High Very High Very High
Acromegaly 30 100.00 Very High Very High Very High
Cancer 630 99.96 Very High Very High Very High
Pituitary Cancer 301 99.96 Very High Very High Very High
Fever 14 99.96 Very High Very High Very High
Diabetes Mellitus 68 99.84 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The changes in diurnal and nocturnal PRL surges during early pregnancy indicate that prior parity reduces the subsequent secretion of PRL, possibly by altering the neuroendocrine regulation of this hormone.
Spec (possibly) Negative_regulation (reduces) of Localization (secretion) of PRL
1) Confidence 0.59 Published 1993 Journal Life Sci. Section Abstract Doc Link 8336523 Disease Relevance 0 Pain Relevance 0.11
Delayed activation of tuberoinfundibular dopamine neurons and suppression of prolactin secretion in the rat after morphine administration.
Negative_regulation (suppression) of Localization (secretion) of prolactin in dopamine neurons associated with dopamine, narcan and morphine
2) Confidence 0.59 Published 1986 Journal J. Pharmacol. Exp. Ther. Section Title Doc Link 3950867 Disease Relevance 0.16 Pain Relevance 1.09
These results indicate that chronic hyperprolactinemia inhibited PRL secretion and enhanced the hyperglycemic stress response in the female rat.
Negative_regulation (inhibited) of Localization (secretion) of PRL associated with stress and galactorrhea
3) Confidence 0.59 Published 1996 Journal Braz. J. Med. Biol. Res. Section Abstract Doc Link 9070395 Disease Relevance 0.59 Pain Relevance 0.05
The experiment examining pituitary PRL concentration at 6:00 or 18:00 hr confirmed that urethane (1.0g/kg) anesthesia suppressed the release of PRL surge from the pituitary.
Negative_regulation (suppressed) of Localization (release) of PRL in pituitary associated with anesthesia
4) Confidence 0.59 Published 1991 Journal Jikken Dobutsu Section Abstract Doc Link 2007438 Disease Relevance 0 Pain Relevance 0.25
We previously reported that the posterior pituitary dopaminergic system participates in the inhibition of prolactin (PRL) secretion in both male and lactating female rats.
Negative_regulation (inhibition) of Localization (secretion) of PRL in posterior pituitary
5) Confidence 0.59 Published 1986 Journal Neuroendocrinology Section Abstract Doc Link 3748304 Disease Relevance 0 Pain Relevance 0.05
Urethane anesthesia, necessary for the surgery attendant to stalk blood collection, did not suppress the surge of PRL secretion induced by cervical stimulation 16-24 h previously.
Neg (not) Negative_regulation (suppress) of Localization (secretion) of PRL in blood associated with anesthesia
6) Confidence 0.59 Published 1979 Journal Endocrinology Section Abstract Doc Link 487998 Disease Relevance 0 Pain Relevance 0.38
Simultaneous injection of melatonin with naloxone methyliodide (2.8 mg/Kg) inhibited PRL release (77.5%) while naloxone methyliodide alone did not modify this secretion.
Negative_regulation (inhibited) of Localization (release) of PRL associated with narcan
7) Confidence 0.59 Published 1995 Journal Endocr. Res. Section Abstract Doc Link 7588425 Disease Relevance 0 Pain Relevance 0.73
On the other hand, whereas animals pretreated with ketanserin or LY53857 (both at a dose of 5 mg/kg BW, ip), two specific 5-HT2 receptor antagonists, had no effect on fentanyl-induced PRL secretion, the same treatment significantly blocked 5-HT-induced PRL secretion.
Negative_regulation (blocked) of Localization (secretion) of PRL associated with antagonist
8) Confidence 0.59 Published 1989 Journal Endocrinology Section Abstract Doc Link 2551630 Disease Relevance 0 Pain Relevance 0.55
Pretreatment with naloxone (0.5 mg/kg BW, ip) did not block the acute phase of PRL secretion, but significantly lowered the PRL level at 30 min.
Negative_regulation (block) of Localization (secretion) of PRL associated with narcan
9) Confidence 0.59 Published 1989 Journal Endocrinology Section Abstract Doc Link 2551630 Disease Relevance 0 Pain Relevance 0.56
Apomorphine was at least as effective an inhibitor of PRL secretion when given 2 h after sulpiride than when injected after saline.
Negative_regulation (inhibitor) of Localization (secretion) of PRL
10) Confidence 0.59 Published 1983 Journal Can. J. Physiol. Pharmacol. Section Abstract Doc Link 6616329 Disease Relevance 0.09 Pain Relevance 0.08
None of the 5-HT antagonists blocked MDMA-induced PRL secretion.
Negative_regulation (blocked) of Localization (secretion) of PRL associated with antagonist
11) Confidence 0.59 Published 1988 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 2898523 Disease Relevance 0.08 Pain Relevance 0.31
Pretreatment with p-chlorophenylalanine (150 mg/kg i.p.) for 3 days depleted cortical and hypothalamic 5-HT and 5-hydroxyindoleacetic acid by approximately 80% and significantly attenuated MDMA-induced corticosterone and PRL secretion.
Negative_regulation (attenuated) of Localization (secretion) of PRL
12) Confidence 0.59 Published 1988 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 2898523 Disease Relevance 0.07 Pain Relevance 0.24
Pre-treatment with either the dopamine agonist, piribedil, or the cholinergic agonist, pilocarpine, resulted in significantly reduced TRH-induced PRL release.
Negative_regulation (reduced) of Localization (release) of PRL associated with dopamine and agonist
13) Confidence 0.59 Published 1986 Journal Life Sci. Section Abstract Doc Link 2934599 Disease Relevance 0 Pain Relevance 0.42
Later injections (at 1530 and 1730 h) had no further suppressive effects, although these injections suppressed the basal PRL secretion occurring during diestrous days I and II to near undetectable levels.
Negative_regulation (suppressed) of Localization (secretion) of PRL
14) Confidence 0.59 Published 1985 Journal Endocrinology Section Abstract Doc Link 4040459 Disease Relevance 0 Pain Relevance 0.53
Prolactin (PRL) secretion from the anterior pituitary is tonically inhibited by tuberoinfundibular dopamine (TIDA) neurons in the arcuate nucleus of the hypothalamus.
Negative_regulation (inhibited) of Localization (secretion) of PRL in arcuate nucleus associated with dopamine
15) Confidence 0.59 Published 2002 Journal Neurosci. Lett. Section Abstract Doc Link 12123859 Disease Relevance 0 Pain Relevance 0.50
Further evidence that central neurotensin inhibits pituitary prolactin secretion by stimulating dopamine release from the hypothalamus.
Negative_regulation (inhibits) of Localization (secretion) of prolactin in pituitary associated with dopamine
16) Confidence 0.59 Published 1986 Journal Proc. Soc. Exp. Biol. Med. Section Title Doc Link 3485291 Disease Relevance 0 Pain Relevance 0.34
Intracerebroventricular (icv) injection of neurotensin (NT) (2 micrograms/rat) suppressed prolactin (PRL) release induced by L-5-hydroxytryptophan (1 mg/100 g body wt, iv), prostaglandin E2(1 microgram/rat, icv), and FK33-824 (10 micrograms/100 g body wt, iv), a Met5-enkephalin analog, in urethane-anesthetized or conscious rats.
Negative_regulation (suppressed) of Localization (release) of PRL in body associated with enkephalin and intracerebroventricular
17) Confidence 0.59 Published 1986 Journal Proc. Soc. Exp. Biol. Med. Section Abstract Doc Link 3485291 Disease Relevance 0 Pain Relevance 0.31
These results suggest that central NT inhibits PRL secretion by stimulating dopamine release from the hypothalamus into hypophysical portal blood in the rat.
Negative_regulation (inhibits) of Localization (secretion) of PRL in hypothalamus associated with dopamine
18) Confidence 0.59 Published 1986 Journal Proc. Soc. Exp. Biol. Med. Section Abstract Doc Link 3485291 Disease Relevance 0 Pain Relevance 0.35
These findings suggest that stimulatory opioid control of PRL secretion and the dopaminergic mechanism which tonically inhibits PRL release are intact in the neonatal rat.
Negative_regulation (inhibits) of Localization (release) of PRL associated with opioid
19) Confidence 0.59 Published 1987 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 3031276 Disease Relevance 0 Pain Relevance 0.83
PRL secretion induced by these serotonergic agents was blocked by cyproheptadine, a serotonin receptor antagonist.
Negative_regulation (blocked) of Localization (secretion) of PRL associated with antagonist and serotonin
20) Confidence 0.59 Published 1987 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 3031276 Disease Relevance 0 Pain Relevance 0.93

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox